Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.

Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Dogs Are Forced To Wear The Things They Steal — And It’s Hilarious
Kitties for Sale: How to Choose a Healthy, Happy Kitten
25 Unforgettable Things to Do in Chicago
Small Acts of Kindness That Change a Stranger’s Entire Day
A Man Thanked the Voice of Mario for His Childhood. Charles Martinet’s Response Was Beautiful
Construction Crew Rescues Kitten From Excavator, Then Gives Her a Job
Two Goats Escape Their Yard and Decide to Catch the Morning Bus
Meet Otter, the Kitten in the Tiny Helmet
Single Dad Adopts Girl with Down Syndrome
This Dog Was Banned From a Store for Stealing. The Day He Returned, He Stole Again
These Tiny Birds Look So Angry, It's Adorable
